75.01
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $75.01, with a volume of 2.00M.
It is down -0.32% in the last 24 hours and up +1.02% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$75.25
Open:
$77.03
24h Volume:
2.00M
Relative Volume:
2.12
Market Cap:
$11.92B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
79.80
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
+3.09%
1M Performance:
+1.02%
6M Performance:
-4.35%
1Y Performance:
+11.34%
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TECH
Bio Techne Corp
|
75.01 | 11.92B | 1.17B | 150.71M | 245.03M | 0.94 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-24 | Downgrade | Citigroup | Buy → Neutral |
Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
Feb-02-24 | Downgrade | Stifel | Buy → Hold |
Dec-07-23 | Initiated | UBS | Buy |
Aug-28-23 | Initiated | William Blair | Outperform |
Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
Feb-23-21 | Upgrade | Stifel | Hold → Buy |
Jan-25-21 | Reiterated | The Benchmark Company | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
May-27-20 | Downgrade | Stifel | Buy → Hold |
May-14-20 | Initiated | The Benchmark Company | Buy |
Jan-08-20 | Resumed | Stephens | Overweight |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Neutral |
Nov-15-19 | Initiated | Stifel | Buy |
Jul-02-19 | Upgrade | Janney | Neutral → Buy |
Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
Oct-17-18 | Initiated | Goldman | Neutral |
Jun-15-18 | Initiated | Argus | Buy |
Jul-13-17 | Initiated | Wells Fargo | Market Perform |
Feb-09-17 | Initiated | Citigroup | Buy |
Jan-18-17 | Initiated | Deutsche Bank | Buy |
Nov-10-16 | Resumed | Leerink Partners | Outperform |
Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
There is no doubt that Bio-Techne Corp (TECH) ticks all the boxes. - SETE News
Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Call Transcript - Insider Monkey
Conestoga Capital Advisors LLC Buys 5,025 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corp (TECH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Bio-Techne (NASDAQ:TECH) Shares Gap Up After Dividend Announcement - Defense World
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket - MSN
Earnings call transcript: Bio-Techne beats Q2 2024 forecasts, stock surges By Investing.com - Investing.com South Africa
Earnings call transcript: Bio-Techne beats Q2 2024 forecasts, stock surges - Investing.com
Bio-Techne Q2 25 Earnings Conference Call At 9:00 AM ET - Nasdaq
Bio-Techne (NASDAQ:TECH) Surprises With Strong Q4, Stock Soars By Stock Story - Investing.com Canada
Bio-Techne earnings beat by $0.03, revenue topped estimates - Investing.com
Bio-Techne Appoints New Board Member and Reports Revenue Growth - TipRanks
Bio-Techne Corp Q2 FY2025 Earnings: Revenue Hits $297M, Adjusted EPS at $0.42, Surpassing Estimates - GuruFocus.com
Bio-Techne (NASDAQ:TECH) Surprises With Strong Q4, Stock Soars - Yahoo Finance
Bio-Techne Delivers Massive Earnings Beat: Cell Therapy Growth Drives Record Quarter - StockTitan
Bio-Techne Declares Dividend - Yahoo Finance
The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS And Align - Barchart
The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS and Align - Yahoo Finance
TECH (Bio-Techne) Revenue : $1,172 Mil (TTM As of Sep. 2024) - GuruFocus.com
Bio-Techne adds Dr. Amy E. Herr to its Board of Directors - Investing.com
Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors - Quantisnow
Trust Point Inc. Has $1.16 Million Stake in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Position Cut by Pacer Advisors Inc. - Defense World
How to Take Advantage of moves in (TECH) - news.stocktradersdaily.com
Kim Kelderman Sells 13,392 Shares of Bio-Techne Co. (NASDAQ:TECH) Stock - MarketBeat
SG Americas Securities LLC Acquires 456 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
TECH Gears Up to Report Q2 Earnings: Here's What to Expect - MSN
Bio-Techne (TECH) Projected to Post Earnings on Wednesday - MarketBeat
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Bio-Techne CEO Kim Kelderman sells $1.04 million in stock - MSN
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Bio-Techne CEO Kim Kelderman sells $1.04 million in stock By Investing.com - Investing.com South Africa
(TECH)Analyzing Bio-Techne's Short Interest - Benzinga
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
GMP Cell Therapy Consumables Market Top PlayersMiltenyi - openPR
First Citizens Bank & Trust Co. Buys 120,275 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
UMB Bank n.a. Buys 168 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Bio-Techne (TECH) Stock Price, News & Analysis - MarketBeat
Bio-Techne (NASDAQ:TECH) Stock Price Down 4.5%Here's What Happened - MarketBeat
Spatial Proteomics Market Report and Competitive Landscape 2025-2030, with 10X Genomics, Bruker, Fluidigm, Akoya Biosciences, PerkinElmer, Biotechne, S2 Genomics, Seven Bridges Genomics & More - GlobeNewswire Inc.
Bio-Techne Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Riverbridge Partners LLC Has $49.47 Million Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Fort Washington Investment Advisors Inc. OH Boosts Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Park Avenue Securities LLC Trims Holdings in Bio-Techne Co. (NASDAQ:TECH) - Defense World
Assenagon Asset Management S.A. Has $3.12 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Holdings Lifted by Assenagon Asset Management S.A. - Defense World
Bio-Techne Co. (NASDAQ:TECH) Receives $82.00 Consensus Target Price from Brokerages - Defense World
ScaleReady Announces a G-Rex® Grant has been awarded to BrainChild Bio - Yahoo Finance
Bio-Techne Earnings Preview: What to Expect - Nasdaq
Bio-Techne Sets Q2 2025 Earnings Call for February 5: Key Financial Updates Coming - StockTitan
Bio-Techne Earnings Preview: What To Expect - Barchart
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):